ClinicalTrialsFinder
RecruitingNot ApplicableNCT05132244

Monitoring and Managing Glucose Levels in People With Pancreatic Cancer

Pancreatic Cancer Glucose Assessment and Regulation Study

Sponsor

British Columbia Cancer Agency

Enrollment

50 participants

Start Date

Apr 16, 2024

Study Type

INTERVENTIONAL

Conditions

Pancreatic CancerPDAC - Pancreatic Ductal AdenocarcinomaHyperglycemia

Summary

This study will investigate the prevalence of hyperglycemia (high blood sugar) in approximately 50 participants with pancreatic cancer. Sugar levels will be monitored with blood draws prior to each cycle of anti-cancer treatment until treatment ends or the participant's cancer worsens. Participants may receive any first-line systemic therapy for pancreatic cancer, including treatments given as part of another clinical trial. If treatment is needed to manage blood sugar levels, the treatment will be given according to the standard of care. All participants will be enrolled into the same group.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study monitors and manages blood sugar levels in people with pancreatic cancer receiving chemotherapy, since high blood sugar can affect treatment outcomes. **You may be eligible if...** - You have been diagnosed with pancreatic ductal adenocarcinoma (the most common type of pancreatic cancer) - You are about to start first-line chemotherapy with FOLFIRINOX - You are 18 or older - You are in good overall health (ECOG 0–1) with adequate blood counts and organ function **You may NOT be eligible if...** - You are not starting FOLFIRINOX chemotherapy - You have poor blood counts or organ function that does not meet required thresholds Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREGlucose Measurements via Blood Draw

Blood glucose levels will be measured using blood drawn prior to each cycle of systemic therapy. Anti-cancer treatment can follow standard care protocols or be given within another clinical trial. Anti-hyperglycemic treatment will be administered when indicated by and following standard care protocols.

Locations(2)

British Columbia Cancer

Vancouver, British Columbia, Canada

Princess Margaret Cancer Centre

Toronto, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05132244

Related Trials

Assessment of Adherence to Remotely Monitored Physical Activity Tracked on a Smartwatch, and Its Impact on Reducing Fatigue 3 Months After Adjuvant Chemotherapy for Cancer

NCT07429487

Remote Exercise and Nutritional Prehabilitation for Pancreatic Cancer

NCT064239631 location

GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites

NCT054384591 location

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

NCT0749144520 locations

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

NCT0725223260 locations